216 related articles for article (PubMed ID: 24955100)
21. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks.
Stoss M; van Wely M; Musielsky H; Gorter RW
Arzneimittelforschung; 1999 Apr; 49(4):366-73. PubMed ID: 10337457
[TBL] [Abstract][Full Text] [Related]
22. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.
Weissenstein U; Kunz M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2016 Aug; 16():271. PubMed ID: 27491866
[TBL] [Abstract][Full Text] [Related]
23. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
Pelzer F; Tröger W; Nat DR
J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Felenda JE; Turek C; Stintzing FC
J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro.
Eggenschwiler J; Patrignani A; Wagner U; Rehrauer H; Schlapbach R; Rist L; Ramos MH; Viviani A
Arzneimittelforschung; 2006 Jun; 56(6A):483-96. PubMed ID: 16927530
[TBL] [Abstract][Full Text] [Related]
26. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro.
Weissenstein U; Kunz M; Oufir M; Wang JT; Hamburger M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2019 Jan; 19(1):23. PubMed ID: 30658716
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident.
Chernyshov VP; Heusser P; Omelchenko LI; Chernyshova LI; Vodyanik MA; Vykhovanets EV; Galazyuk LV; Pochinok TV; Gaiday NV; Gumenyuk ME; Zelinsky GM; Schaefermeyer H; Schaefermeyer G
Am J Ther; 2000 May; 7(3):195-203. PubMed ID: 11317168
[TBL] [Abstract][Full Text] [Related]
28. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro.
Kelter G; Fiebig HH
Arzneimittelforschung; 2006 Jun; 56(6A):435-40. PubMed ID: 16927523
[TBL] [Abstract][Full Text] [Related]
29.
Klingemann H
Front Vet Sci; 2023; 10():1285354. PubMed ID: 38234984
[TBL] [Abstract][Full Text] [Related]
30. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata).
Eggenschwiler J; von Balthazar L; Stritt B; Pruntsch D; Ramos M; Urech K; Rist L; Simões-Wüst AP; Viviani A
BMC Complement Altern Med; 2007 May; 7():14. PubMed ID: 17493268
[TBL] [Abstract][Full Text] [Related]
31. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
32. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
Zuzak TJ; Wasmuth A; Bernitzki S; Schwermer M; Längler A
Complement Ther Med; 2018 Oct; 40():198-202. PubMed ID: 30219449
[TBL] [Abstract][Full Text] [Related]
33. Characterization of cytotoxic proteins from mistletoe (Viscum album L.).
Jung ML; Baudino S; Ribéreau-Gayon G; Beck JP
Cancer Lett; 1990 May; 51(2):103-8. PubMed ID: 2344587
[TBL] [Abstract][Full Text] [Related]
34. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
Stein G; Berg PA
Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
[TBL] [Abstract][Full Text] [Related]
35. [Lectins in Viscum:a progress review].
Li JQ; Yang B
Zhongguo Zhong Yao Za Zhi; 2021 Jul; 46(14):3551-3559. PubMed ID: 34402277
[TBL] [Abstract][Full Text] [Related]
36. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities.
Schink M; Dehus O
BMC Complement Altern Med; 2017 Dec; 17(1):521. PubMed ID: 29202738
[TBL] [Abstract][Full Text] [Related]
37. [Viscum album L. (Iscador) in the cat: tolerance, adverse reactions and indications].
Glardon ; Pache ; Magnenat ; Pin ; Parvis
Schweiz Arch Tierheilkd; 2014 Aug; 156(8):381-8. PubMed ID: 25082635
[TBL] [Abstract][Full Text] [Related]
38. Structure and properties of polysaccharides from Viscum album (L.).
Jordan E; Wagner H
Oncology; 1986; 43 Suppl 1():8-15. PubMed ID: 3808577
[TBL] [Abstract][Full Text] [Related]
39. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series.
Gardin NE
Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944
[TBL] [Abstract][Full Text] [Related]
40. Viscum album L. Therapy in Oncology: An Update on Current Evidence.
Thronicke A; Schad F; Debus M; Grabowski J; Soldner G
Complement Med Res; 2022; 29(4):362-368. PubMed ID: 35325897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
